Background
On June 15, 2026, Splash Beverage Group, Inc. (NYSE American: SBEV) announced the completion of a CAD 300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and pharmaceutical product development.
Significance of the Investment
This investment aligns with Splash's previously announced transformation into a cannabinoid-based health, wellness, and healthcare-focused platform company. Splash believes that Avicanna has built one of the most sophisticated cannabinoid healthcare platforms and is uniquely positioned for the continued evolution of the medical cannabinoid market in the United States.
Key Strengths of Avicanna
- Leading Biopharmaceutical Position: One of North America's leading cannabinoid biopharmaceutical companies with proprietary formulations and clinical-stage assets.
- Commercial-Stage Product Portfolio: Includes Trunerox™, an approved treatment for severe epilepsy, and multiple clinical programs targeting pain, inflammation, and dermatological conditions.
- Patient Care Platform: MyMedi.ca is one of Canada's leading medical cannabis care platforms, offering pharmacist-led patient care, reimbursement support, and insurance adjudication.
- Regulatory Compliance Experience: Real-world operating experience within Canada's federally regulated medical cannabis system.
- Vertically Integrated Platform: Pharmaceutical-grade cannabinoid manufacturing and active pharmaceutical ingredient production through its operations in Colombia.
- Experienced Management Team: Deep expertise across healthcare, pharmaceuticals, clinical research, and cannabinoid medicine.
- Debt-Free Balance Sheet: Financially sound.
Future Outlook
Splash believes the long-term cannabinoid opportunity will increasingly be defined by clinical evidence, physician participation, healthcare integration, reimbursement infrastructure, and regulatory compliance. Avicanna has already built a platform around these principles and may be particularly well positioned as the U.S. healthcare and regulatory environment continues to evolve.
Brady Cobb, Interim CEO of Splash Beverage Group, stated: 'In many respects, Avicanna has built and operated within a federally regulated medical cannabinoid framework that already incorporates many of the characteristics increasingly being evaluated across the United States healthcare system. We view this investment as a strategic allocation into a company whose platform, capabilities, and operating experience may be uniquely suited for the next phase of cannabinoid medicine.'
Investment Details
On June 9, 2026, Splash completed a CAD 300,000 investment in Avicanna's non-brokered private placement, acquiring 2,000,000 common shares and 1,000,000 warrants.